Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial . Lancet (2011) 6736 :60931–8.10.1016/S0140-6736(11)60931-8 [ Cross Ref ]Sherry N, Hago
Teplizumab (PRV-031) is a humanized IgG1k that binds to an epitope of the CD3-epsilon chain expressed on mature T lymphocytes and thereby modulates the pathological immunologic responses underlying type 1 diabetes (T1D) and other autoimmune diseases. ...
teplizumab上市后，临床医生将可以干预并从根本上改变这些高危受试者的T1D进展。原文出处：Provention Bio Completes Rolling Submission of the Biologics License application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals 注：以上资讯来源于网络，由香港...
^American Diabetes Association Professional Practice Committee. 3. Prevention or Delay of Type 2 Diab...
Hematopoietic Stem Cells in Type 1 Diabetes. PMID: 34305929 Immunomodulators: Cell savers. PMID: 22616095 Traveling down the Long Road to Type 1 Diabetes Mellitus Prevention. PMID: 31180193 Prevention of type 1 diabetes: where we are and where we are going. PMID: 34286946 ...
Teplizumab delays onset oftype1 diabetes mellitusDisease preventionRandomized controlled trialsType 1 diabetesdoi:10.1038/s41574-019-0233-3Alan MorrisNature Reviews Endocrinology
原文出处:Provention Bio Provides Regulatory Update on Biologics Licenseapplication for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-Risk Individuals 版权声明 本网站所有注明“来源:生物谷”或“来源:bioon”的文字、图片和音视频资料,版权均属于生物谷网站所有。非经授权,任何媒体...
Teplizumab in Relatives at Risk for Type 1 Diabetes. Reply. PMID: 31693818 Investigational therapies targeting CD3 for prevention and treatment of type 1 diabetes. PMID: 34936848 Therapeutic anti-CD3 monoclonal antibodies: from bench to bedside. PMID: 27161438 ...
today announced the submission of the clinical module of the Company's Biologic License Application (BLA) to the U.S. Food and Drug Administration (FDA) for teplizumab (PRV-031), an investigational anti-CD3 monoclonal antibody for the delay or prevention of clinical Type 1 Diabetes (T1D) ...
原文出处:Provention Bio Completes Rolling Submission of the Biologics License application (BLA) for Teplizumab for the Delay or Prevention of Clinical Type 1 Diabetes in At-risk Individuals 注:以上资讯来源于网络,由香港济民药业整理编辑(如有错漏,请帮忙指正),只为提供全球最新上市药品的资讯,帮助中国...